Invasive Ductal Breast Carcinoma Recruiting Phase 1 / 2 Trials for Talimogene laherparepvec (DB13896)

Also known as: Invasive Ductal Breast Cancer / Carcinoma, Ductal, Breast / Infiltrating ductular carcinoma / Breast ductal cancer invasive / Breast ductal cancer infiltrating / Infiltrating ductal breast cancer

IndicationStatusPhase
DBCOND0047004 (Invasive Ductal Breast Carcinoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02779855Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast CancerTreatment